Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,820 people get PSTI articles and Market Currents by email alert.

Get email alerts on PSTI »

PSTI

Pluristem Therapeutics, Inc.

5/25/2013, 3:24 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 11:02 AM Pluristem Therapeutic (PSTI +1%) ticks higher after reporting its PLX cells tested in preclinical animal models of preeclampsia effectively improved several parameters of the disease. Details of the study will be presented on May 30th at the Society for Gynecological Investigation Summit in Jerusalem. Comment! [Healthcare, On the Move]
Wednesday, April 24, 9:11 AM Premarket gainers: BKI +26%. PBTH +11%. LL +7%. PSTI +5%.
Losers: VOCS -31%. UIS -20%. EW -19%. RES -13%. AWAY -9%. SCON -9%. JNPR -7%. SVU -7%. PNRA -6%. CREE -6%. Comment! [On the Move]
Thursday, April 18, 12:09 PM Pluristem Therapeutics (PSTI -1.4%) expands its presence in the orthopedic and sports medicine markets with plans to initiate a Phase I clinical trial to evaluate the safety and efficacy of the local administration of PLX cells to patients suffering from injuries to tendons. PSTI believes that its PLX-PAD cells will improve the post-operative structural and functional status of the rotator cuff. Comment! [Healthcare]
Thursday, April 11, 11:15 AM United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells. 1 Comment [Healthcare, On the Move]
Wednesday, March 20, 8:56 AM Pluristem Therapeutics (PSTI) says the first group of six patients have received its PLacental Expanded cells or a placebo in a Phase I/II trial to test the therapy for treating surgically induced muscle injury. None of the patients have suffered significant side effects so far. Three groups of six patients will be enrolled in the trial. Shares +2% in Tel Aviv. (PR) Comment! [Healthcare]
Wednesday, February 20, 2:32 PM Pluristem Therapeutics (PSTI +4%) pops on reports that the FDA has granted orphan status for its PLX Cells to treat aplastic anemia. 1 Comment [Healthcare, On the Move]
Tuesday, January 15, 8:34 AM Pluristem Therapeutics (PSTI) climbs 6.5% after the developer of placenta-derived cell therapies receives German approval to start a Phase II study of its PLX-PAD cells in patients with Intermittent Claudication (IC), a subset of Peripheral Artery Disease that is characterized by muscle pain, numbness and fatigue, especially in the calf muscle. Around 14M people suffer from IC in the U.S. 1 Comment [Healthcare, On the Move]
Wednesday, November 21, 2012, 12:08 PM Pluristem (PSTI +2.5%) says the FDA has acknowledged that aplastic anemia is a rare disease, confirming that potential treatments for the condition are eligible for orphan drug status. However, it also has requested that PSTI provide additional information and data for further analysis before the agency can determine if PLX cells can qualify for orphan drug designation for aplastic anemia. PSTI is focusing on the use of the cells to treat systemic diseases eliminate the need to use the intravenous route. 3 Comments [Healthcare, On the Move]
Friday, November 9, 2012, 9:10 AM Premarket gainers: ZIP +27%. KYAK +26%. LGF +9%. ENR +8%. PSTI +8%. IGT +7%. WCRX +6%. ISIS +5%.
Losers: GRPN -23%. MTG -15%. ARRY -12%. PGRX -12%. SPRD -10%. JCP -8%. PVR -6%. CPIX -5%. DIS -5%. 1 Comment [On the Move]
Friday, November 9, 2012, 9:04 AM Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading." 4 Comments [Healthcare, On the Move]
Thursday, November 8, 2012, 9:10 AM Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move]
Tuesday, November 6, 2012, 9:11 AM Premarket gainers: JIVE +14%. ROSG +9%. PSTI +8%. ACAD +7%. MIPS +6%. LF +6%. CTRP +5%. VRNG +5%.
Losers: SREV -33%. Z -16%. ESRX -11%. FOSL -10%. VVUS -5%. NVO -5%. Comment! [On the Move]
Wednesday, October 17, 2012, 11:18 AM Pluristem Therapeutics (PSTI +1%) gains after saying that preclinical and in in-vitro studies using it's Placental expanded cells resulted in a reduction of fibrotic processes. The data will be presented at the 3rd Annual Meeting of the Israel Society for Placenta Research on October 18. Comment! [Healthcare]
Thursday, September 13, 2012, 10:39 AM Pluristem Therapeutics (PSTI -13.6%) takes a hit after pricing its offering of 8M units at $4 each, a 12% discount to yesterday's close. The units each include one share of common stock and a warrant to purchase 0.35 of a share. 3 Comments [Healthcare, On the Move]
Thursday, September 13, 2012, 9:10 AM Premarket gainers: EQIX +14%. VICL +13%. APRI +13%. LRN +10%. PLL +7%. CTIC +5%.
Losers: CCRT -29%. PSTI -17%. FMER -7%. USG -6%. HK -5%. 1 Comment [On the Move]
Wednesday, September 12, 2012, 4:56 PM Pluristem Therapeutics (PSTI) says it intends to offer an undisclosed sum of common stock and warrants. Jefferies is acting as sole book-running manager, with Oppenheimer acting as co-lead. The company plans to use the funds to conduct clinical trials, research and product development activities and for general corporate purposes. Shares -11.8% AH. Comment! [Healthcare, On the Move]